Buzzkill Labs Closes Oversubscribed Series A Financing
05/17/23, 2:08 PM
Location
livermoreIndustry
information technology
Round Type
series a
Investors
Poseidon
Buzzkill Labs ("Buzzkill"), developer of the world's first rapid saliva test for psychoactive THC, today announced the close of an oversubscribed Series A funding round co-led by Poseidon and existing investors. Buzzkill will use the proceeds from the financing to commercialize its technology, which fills employers' critical need to maintain safe workplaces while respecting the dignity of employees who legally use cannabis outside of work.
Company Info
Location
1911 2nd street
livermore, california, united states
Additional Info
Buzzkill Labs is modernizing drug testing for a world of legal cannabis. We are developing and commercializing portable, rapid, cost-effective testing of oral fluid (saliva) that distinguishes and measures THC parent compound, the psychoactive component of cannabis that causes impairment. Our technology helps to eliminate cheating and to determine current potential impairment versus past use with no interference from CBD or metabolites in 15 minutes.